Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma

被引：0

作者：

Corcoran, Sean R. ^{[1
,2
,3
]}

Choi, Jaewoo ^{[4
]}

Fenner, Rachel E. ^{[1
]}

Yu, Xin ^{[4
]}

Scheich, Sebastian ^{[5
]}

Hsiao, Tony ^{[6
]}

Schevchenko, Galina ^{[1
]}

Morris, Vivian M. ^{[4
]}

Phelan, James D. ^{[4
]}

Papachristou, Evangelia K. ^{[7
]}

Kishore, Kamal ^{[7
]}

D'Santos, Clive S. ^{[8
]}

Ji, Yanlong ^{[9
]}

Pittaluga, Stefania ^{[10
]}

Wright, George ^{[11
]}

Urlaub, Henning ^{[12
]}

Pan, Kuan-Ting ^{[13
]}

Oellerich, Thomas ^{[14
]}

Muppidi, Jagan R. ^{[4
]}

Hodson, Daniel James ^{[15
]}

Staudt, Louis M. ^{[4
]}

机构：

[1] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[2] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA

[3] NCI, Lymphoid Malignancies Branch, NIH, Boston, MA USA

[4] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD USA

[5] Goethe Univ, Frankfurt, Germany

[6] NCI, NIH, Bethesda, MD USA

[7] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England

[8] Univ Cambridge, Cambridge, England

[9] Max Planck Inst Multidisciplinary Sci, Gottingen, Germany

[10] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD USA

[11] NCI, Biometr Res Program, Div Canc Treatment & Diag, NIH, Bethesda, MD USA

[12] Max Planck Inst Biophys Chem, Gottingen, Germany

[13] MPI Biophys Chem, Gottingen, Germany

[14] Goethe Univ, Frankfurt, Germany

[15] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178059

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
Russler-Germain, David A.
Cliff, Edward R. Scheffer
Bartlett, Nancy L.
BLOOD, 2023, 142 (25) : 2216 - 2219
[22] Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
Rita Assi
Nohad Masri
Iman Abou Dalle
Jean El-Cheikh
Hady Ghanem
Ali Bazarbachi
Clinical Hematology International, 2021, 3 (1) : 21 - 26
[23] Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma
Leveille, Etienne
Kothari, Shalin
Cosgun, Kadriye N.
Mlynarczyk, Coraline
Mueschen, Markus
CANCER DISCOVERY, 2024, 14 (09) : 1577 - 1580
[24] Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis☆
Farooqi, Hanzala Ahmed
Ullah, Muhammad Saffi
Raza, Ahmed
Sadiq, Zain
Shaikh, Wardah Ali
Muhammad, Rahmah
Hussain, Muhammad Shoaib
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 207
[25] US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
Matasar, Matthew
Masaquel, Anthony
S. Ho, Rodrigo
Launonen, Aino
Ng, Carmen D.
Wang, Rongrong
Fox, David
Hossain, Farah
Li, Jia
Burke, John M.
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1134 - 1144
[26] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
Amaya, M. L.
Jimeno, A.
Kamdar, M.
DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
[27] Diffuse large B-cell lymphoma - Molecular heterogeneity of diffuse large B-cell lymphoma
Gascoyne, RD
HEMATOLOGY JOURNAL, 2004, 5 : S144 - S148
[28] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
Vodicka, Prokop
Benesova, Katerina
Janikova, Andrea
Prochazka, Vit
Belada, David
Mocikova, Heidi
Steinerova, Katerina
Duras, Juraj
Karban, Josef
Hanackova, Veronika
Sykorova, Alice
Obr, Ales
Trneny, Marek
EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
[29] Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma
Varma, Gaurav
Wang, Jacqueline
Diefenbach, Catherine
EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 795 - 803
[30] Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type
Satoko Oka
Kazuo Ono
Masaharu Nohgawa
Annals of Hematology, 2022, 101 : 2353 - 2354

← 1 2 3 4 5 →